Key statistics
On Friday, Sandoz Group AG (SDZ:SWX) closed at 40.14, -1.21% below its 52-week high of 40.63, set on Nov 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 40.24 |
---|---|
High | 40.46 |
Low | 40.05 |
Bid | 40.00 |
Offer | 40.50 |
Previous close | 39.85 |
Average volume | 1.16m |
---|---|
Shares outstanding | 440.00m |
Free float | 431.07m |
P/E (TTM) | -- |
Market cap | 17.72bn CHF |
EPS (TTM) | -- |
Annual div (ADY) | 0.45 CHF |
---|---|
Annual div yield (ADY) | 1.12% |
Div ex-date | May 03 2024 |
Div pay-date | May 07 2024 |
Data delayed at least 15 minutes, as of Nov 08 2024 16:37 GMT.
More ▼
- Sandoz reports third-quarter and nine-month 2024 sales
- Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position
- Sandoz reports second-quarter sales and half-year 2024 results
- Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases
- FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
- Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
- Sandoz reports first quarter 2024 sales
- Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
- Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
- Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
More ▼